MedTrace Logo

Intravenous Administration of Microplasmin for Treatment of Acute Ischemic Stroke

NCT00123305 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2014-11-07

No results posted yet for this study

Summary

The primary purpose of this study is to evaluate the safety and preliminary efficacy of microplasmin when administered intravenously to patients who have suffered an acute stroke within 12 hours before randomization.

Conditions

  • Stroke, Acute

Interventions

DRUG

Microplasmin

1mg/kg bolus of microplasmin solution followed by 1,2 or 3mg/kg infusion of mircroplasmin solution.

DRUG

Microplasmin

1mg/kg bolus of placebo solution followed by 1,2 or 3mg/kg infusion of placebo solution

Sponsors & Collaborators

  • ThromboGenics

    lead INDUSTRY

Principal Investigators

  • Vincent Thijs, MD PhD · KU Leuven

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-10-31
Primary Completion
2008-05-31
Completion
2008-06-30

Countries

  • Austria
  • Belgium
  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00123305 on ClinicalTrials.gov